We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Millipore Acquires Remaining Ownership of Joint Venture in India

By LabMedica International staff writers
Posted on 01 Dec 2009
Millipore Corp. More...
(Billerica, MA, USA) has acquired the remaining 60% ownership of its joint venture in India, Millipore India Pvt., Ltd. The transaction will accelerate strategic growth initiatives in India's thriving life science market.

Based in Bangalore, Millipore India is primarily a sales, service, and manufacturing organization that has additional offices in Ahmedabad, Hyderabad, Kolkata, Mumbai, and Delhi. The joint venture's revenues are split evenly between Millipore's Bioprocess and Bioscience divisions.

The new subsidiary will enable Millipore to invest in initiatives that will drive growth and expand its leadership in India's thriving life-science market. India represents a critical part of the company's strategy to increase its growth by expanding its presence in BRICS (Brazil, Russia, India, China, and Singapore) countries.

There are more than 80 plants in India approved by the United States Food and Drug Administration (FDA; Silver Spring, MD, USA) to manufacture drugs, and the country accounts for almost 25% of the global generic drug market. In addition, the Indian government has invested US$1.7 billion to expand the country's life science and biotechnology industries and several Indian companies have emerged as global competitors in the biopharmaceutical industry.

"India has experienced unprecedented levels of investment and expansion in the country's biotechnology, pharmaceutical, and life science research industries,” said Martin Madaus, chairman & CEO of Millipore. "By establishing direct operations in the country, we will be able to more effectively execute our strategy and leverage our unique capabilities to accelerate growth and support our growing customer base in this dynamic market.”

Related Links:

Millipore
United States Food and Drug Administration




New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.